This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2001;285:724.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved tacrolimus ointment (Protopic; Fujisawa Healthcare, Deerfield, Ill) for short-term and intermittent long-term therapy for patients with moderate to severe atopic dermatitis in whom the use of coventional therapies is inadvisable or not adequately effective.The indication is for 0.03% and 0.1% tacrolimus for adults and 0.03% for children 2 to 15 years.

The FDA approval was based on results of three randomized, vehicle-controlled, 12-week studies and two 1-year studies with patients with moderate to severe eczema who were not refractory to other treatment. One of the 12-week studies included 351 patients 2-15 years of age, and the other two included a total of 632 patients aged 15-79 years. At baseline, 58% of the patients had severe disease; the mean body surface area affected was 46%. More than 80% of patients had eczema affecting the face and/or neck region.

In the pediatric study, 36% of patients in the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Analogous oligo-acyl-lysines with distinct antibacterial mechanisms
Rotem et al.
FASEB J. 2008;22:2652-2661.
ABSTRACT | FULL TEXT  

Systemic Adverse Effects After Botulinum Toxin Type B (Myobloc) Injections for the Treatment of Palmar Hyperhidrosis
Baumann and Halem
Arch Dermatol 2003;139:226-226.
FULL TEXT